Home > News > Nucryst Looks to Zap Zits
March 10th, 2006
Nucryst Looks to Zap Zits
Jack Uldrich: Yesterday, Nucryst announced that it had been granted a new patent that covers the company’s poprietary nanocrystalline silver for treating acne.
Given the number of teenagers that still suffer from this vexing condition, the patent could prove to be very profitable for the company. In my estimation, however, this news alone is not enough to change my bearish opinion of Nucryst.
Harris & Harris Group Notes the Receipt of Proceeds From the Sale of Molecular Imprints' Semiconductor Business to Canon April 22nd, 2014
Harris & Harris Group Continues Its Blog Series to Highlight Most Impactful Portfolio Companies With Champions Oncology, Inc. April 17th, 2014
Nanometrics to Announce First Quarter Financial Results on April 29, 2014 April 9th, 2014
Harris & Harris Group Notes Mersana's Collaboration Agreement With Subsidiary of Takeda Pharmaceutical Co. April 8th, 2014